The World's First Hospital: I Build A Palace Of Medicine

the end of August.

New Jersey.

Johnson & Johnson headquarters.

Joaquin took a document and knocked on the door of the CEO's office.

He handed the document to Alex, the CEO, and reported: "BOSS, the laboratory has analyzed Yinhe Manlu Capsules and found that the new drug has a significant effect on Alzheimer's disease."

After reading through the documents in detail, Alex frowned.

Since 1998, Johnson & Johnson, Roche, Pfizer, Eli Lilly, Merck, Bayer, AstraZeneca and other top global pharmaceutical companies have invested more than US$600 billion in research and development in the field of Alzheimer's disease.

But most of the funds were wasted.

Most of the new drugs developed have failed in the first phase of clinical trials.

New drug research and development is as difficult as climbing the sky!

The reason why these pharmaceutical companies are so persistent.

There are two main reasons.

First, there are 50 million AD patients in the world. From an economic point of view, this field is a blue ocean.

Second, among the top ten causes of death in the country, the only disease that lacks effective treatment is AD.

Yinhe Pharmaceutical Group has now developed a new drug for AD with significant curative effect.

This undoubtedly means.

In the future, the field of Alzheimer's disease will be respected by Yinhe Pharmaceutical Group!

major pharmaceutical companies around the world.

None can compete with it!

Think here.

25 Alex knocked on the table and said in a concentrated voice: "The market in the field of Alzheimer's disease is more than one trillion US dollars. It's really not reconciled to be taken away by Yinhe Pharmaceutical Group like this!"

Jacqueline Hui reported: "Boss, there is also bad news from the lab.

The phase II clinical trial of the BACE inhibitor we developed failed.

The research and development of the drug cost the company $3.6 billion.

If the bapineuzumab monoclonal antibody drug that failed the phase II clinical trial in 2012 is included, the company lost more than 6.5 billion yuan in the field of AD in the past five years!"

hear this.

Alex sighed.

6.5 billion US dollars in research and development expenses, just in vain.

Although Johnson & Johnson is the world's number one pharmaceutical company, it cannot afford the years of losses in drug research and development.

Go on like this.

I'm afraid his position as CEO will be unstable!

Johnson & Johnson is the leader in the pharmaceutical industry. As the CEO of the company, he can be called the strongest "worker" in the medical industry, with an annual salary of 29.58 million US dollars.

If you lose this position.

In the future, I will never find a job with a satisfactory salary.

Alex asked: "Pfizer, Roche, Eli Lilly and other companies, how is the progress of drug development?"

Joaquin quickly replied: "Pfizer has announced that it will no longer try to develop new AD drugs due to high research and development costs and poor efficacy.

The gantenerumab monoclonal antibody drug previously developed by Roche failed in phase II clinical trials.

Eli Lilly's previously developed zap inhibitor failed in phase II clinical trials.

The BACE inhibitor verubecestat drug previously developed by Merck has been discontinued.

The BACE inhibitor lanabecestat previously developed by AstraZeneca failed in phase II clinical trials.

The aducanumab drug previously developed by Biogen/Eisai failed in clinical trials. "

The voice fell.

Alex felt a little better.

To make innovative medicines, you are close to death.

To make an innovative drug for AD, one death is one death.

Now the world's top pharmaceutical companies are unable to develop AD drugs, at least he, the CEO, will not be dismissed.

As for the appearance of Milky Way nectar, it is a "crime other than war".

Who would have thought.

Yinhe Manlu, instead of taking the two R&D routes of BACE and AB, chooses to start from the intestinal bacteria.

Reshape the balance of intestinal flora.

As difficult as it sounds.

But Yinhe Pharmaceutical Group has really done it!

Moreover, the total R&D cost of the enterprise seems to be two to three hundred million yuan in Xia Guobi.

Not even $50 million...

At this time, Jacqueline suggested: "Boss, since we have developed a new drug for AD, why not change the direction of research and development to a generic drug of Yinhe Ganlu Capsules. What do you think?"

"Generic drugs........."

Alex laughed at himself: "As a leading company in the pharmaceutical field, it is too cheap for us to make generic drugs of Yinhe Pharmaceutical Group.

Jacqueline nodded.

The so-called generic drugs, that is, copycat drugs.

However, it is very difficult for generic drugs to be marketed.

The US FDA stipulates that generic drugs must be identical to other generic patented drugs in terms of active ingredients, dosage, safety, efficiency, effects, side effects, and targeting diseases.

Johnson & Johnson is the number one pharmaceutical company in the world, so there is no reason to make a generic drug of Yinhe Manlu!

TO......

Alex changed the subject and said: "The price drop is the price drop, and generic drugs still have to be done! Otherwise, Johnson & Johnson's current research and development capabilities alone will not be able to compete with Yinhe Manlu Capsules at all!"

Listen to this.

Jacqueline was taken aback for a moment.

Then he nodded helplessly.

Start generic drug development now.

Clinical trials need to be repeated.

The time to market must be many years later than Milky Way Manna.

But at least.

Milky way manna eats meat.

Johnson & Johnson generics can have some soup.

Yinhe Pharmaceutical Group can be considered proud enough to make Johnson & Johnson bow its head and make generic drugs!

Sudden.

Secretary Martha hurriedly knocked on the door and came in.

She held a document and said to Alex: "Boss, it's not good, there are many new drugs approved by Yinhe Pharmaceutical Group!"

Alex took the file and looked at it.

Suddenly stunned.

I saw that there was a lot of new drug listing information on it.

The world's first targeted drug for cholangiocarcinoma - Pemitinib (Yinhe Pharmaceutical Group) was approved for marketing!

The world's first innovative drug for the treatment of neurofibromatosis --- Selumetinib (Yinhe Pharmaceutical Group), has been approved for marketing!

The world's first innovative drug for progeria and related syndromes - Zuojinwei (Galaxy Pharmaceutical Group), has been approved for marketing!

The world's first innovative biologic agent for the treatment of thalassemia —————————— Roxip (Galaxy Pharmaceutical Group), has been approved for marketing!

The world's first innovative drug for the treatment of advanced gastrointestinal stromal tumors——Ripretinib (Galaxy Pharmaceutical Group), has been approved for marketing!

The world's first innovative drug for the treatment of attention deficit hyperactivity disorder in children - veloxazine (Yinhe Pharmaceutical Group), has been approved for marketing!

The world's first targeted drug for the second-line treatment of advanced gastric cancer——Remoxiumab (Galaxy Pharmaceutical Group), has been approved for marketing!

The world's first drug for the treatment of primary HLH high-refractory inflammatory syndrome --- Emaliumab (Galaxy Pharmaceutical Group), has been approved for marketing!

The world's first biological agent covering systemic indications of lupus erythematosus and lupus nephritis --- belimumab (Galaxy Pharmaceutical Group), has been approved for marketing!

The world's first Factor Xa anticoagulant inhibitor for specific children and adolescents under the age of 18 - Varoxaban Tablets (Galaxy Pharmaceutical Group), has been approved for marketing!

Alex scanned it carefully.

He was surprised to find that there were 200 new drugs on the file.

Each new drug of Yinhe Pharmaceutical Group is a unique innovative drug.

At this moment, he fell into a deep shock.

Jacqueline, who was on the side, leaned over and took a look.

He asked inappropriately at 430: "Boss, shall we continue to copycat... No, shall we continue to make innovative drugs of these drugs?"

"Let me think about it."

Alex waved his hand weakly: "There are so many new medicines, if you want to imitate them all, what's the point?

Johnson & Johnson has its own development plan every year.

Using a lot of manpower and material resources to make generic drugs is not worth the candle.

You go out first and leave me alone. "

Secretary Martha and assistant Jacqueline nodded and turned to leave.

In the office.

Alex let out a long sigh.

He was very clear.

Yinhe Pharmaceutical Group is already the lifelong enemy of Johnson & Johnson!

With the R & D and listing of Yinhe Ganlu Capsules alone, Yinhe Pharmaceutical Group can rise rapidly and seize the global market.

And 200 new drugs were approved for marketing.

It proves that Yinhe Pharmaceutical Group has strong research and development capabilities in various drug fields.

Facing such a strong rising star.

The future of Johnson & Johnson seems to be clouded!

at the same time.

Pfizer, Novartis, Merck, Roche, Bayer, Eli Lilly, AbbVie, GlaxoSmithKline, AstraZeneca and other top global pharmaceutical companies are trembling.

The research and development capabilities of Yinhe Pharmaceutical Group are really against the sky!

Think about it too.

The world's top pharmaceutical companies have seven or eight national drug laboratories, which is already remarkable.

And Yinhe Pharmaceutical Group is backed by 500 national scientific research institutions.

How does this make them play?

Can we still have fun in the future?

In addition, the first drug developed by Yinhe Pharmaceutical Group is Yinhe Manlu Capsule, which has obvious curative effect on Alzheimer's disease.

Your start is a king bomb.

Isn't this bullying!

All of a sudden, the world's top pharmaceutical companies shut themselves down one after another...